Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Q1 2026 Earnings Presentation
19 slides from Inovio Pharmaceuticals's earnings presentation, May 13, 2026
Slide 1: First Quarter 2026 Financial Results
First Quarter 2026 Financial Results May 2026
Slide 2: Agenda
Agenda Introduction Jennie Willson, Director, Communications CEO Perspective & Corporate Progress Jacqueline Shea, PhD, President & Chief Executive Officer INO-3107 Update Michael Sumner, MBBS, MBA, Chief Medical Officer & Head of Development Steve Egge, MBA, Chief Commercial Officer Pipeline Update
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 4: 1Q26 Corporate Update
1Q26 BLA for INO-3107 Corporate • Focus: advancing INO-3107 through the regulatory process Update - BLA in active review under the Accelerated Approval Program - PDUFA target date set for October 30, 2026 - FDA reiterated intent to schedule informal meeting to discuss potential review issue noted in
Slide 5: Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis (RRP)
Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis (RRP) • BLA accepted by FDA for review under Accelerated Approval program • PDUFA target date of Oct. 30, 2026
Slide 6: INO-3107 Regulatory Update
INO-3107 Regulatory Update BLA for INO-3107 under active review since December 2025 • Responding to routine requests from FDA • FDA completed mid-cycle review, no new significant issues with BLA reported by FDA • Late-cycle review meeting scheduled for 3Q26 Awaiting response from FDA: • FDA reiterat
Slide 7: Accelerated Approval: We Believe INO-3107 Meets FDA Criteria
INO-3107 Accelerated Approval: We Believe INO-3107 Meets FDA Criteria1 Meaningful therapeutic benefit Potential to meet remaining over existing treatments critical unmet need EFFICACY SAFETY DIFFERENTIATED MOA • 50% - 100% reduction in surgeries: • No required minimal residual • Ability to treat pat
Slide 8: Why every surgery matters to RRP patients
Why every surgery matters to RRP patients: “ The cumulative risk for injury increases with every surgery, but ultimately it only takes one surgical misadventure to permanently damage the larynx.” Factors Associated with Iatrogenic Laryngeal Injury in RRP Otolaryngology, 2024 Apr;170(4):1091-1098. do
Slide 9: Surgery Should Be a Last Resort, Not a First-line Treatment
INO-3107 Surgery Should Be a Last Resort, Not a First-line Treatment INO-3107: RRP-001 PHASE 1/2 Open-label study at 8 sites (Patients with 2+ surgeries in year prior to treatment) Baseline: DAY 0 WEEK 52 • Initial Surgery: up to 14 days before first dose Patients Enrolled 4 Doses of INO-3107 Comple
Slide 10: Advancing Commercial Readiness Plans
INO-3107 Advancing Commercial Readiness Plans Product Strategy: • Completed market research to understand unmet medical needs and customer perspective • Completed targeting, segmentation and product positioning work – supporting positive differentiation • Developed pricing strategy with price optimi
Slide 11: Key Insights from COSM - Premier Conference for RRP Specialists
INO-3107 Key Insights from COSM - Premier Conference for RRP Specialists High unmet need for effective, non-surgical treatment remains Physicians emphasized importance of having immunotherapy options that can work for each patient Key takeaway: meaningful marketplace with high commercial opportunity
Slide 12: Pipeline Update
Pipeline Update
Slide 13: Innovative Partnership to Advance Novel Combination Therapy for Glioblastoma (GBM)
INO-5412 Innovative Partnership to Advance Novel Combination Therapy for Glioblastoma (GBM) • GBM: most common and aggressive form of brain cancer - ~ 15,000 people diagnosed with GBM each year - Poor prognosis: typical life expectancy of 15-18 months, 5-year survival rate <10% • INO-5412 + cadonili
Slide 14: Potential as a New Treatment Paradigm in Rare Diseases
DPROT DNA-ENCODED PROTEINS Potential as a New Treatment Paradigm in Rare Diseases • Builds on DMAb technology FACTOR VIII PROTEIN STRUCTURE - Targets long-term protein expression, with ability to re-dose due to lack of anti-vector immunity • Aims to address shortcomings of conventional therapeutic p
Slide 15: First Quarter 2026 Financial Update
First Quarter 2026 Financial Update
Slide 16: Achieving Strategic Goals While Reducing Costs
Achieving Strategic Goals While Reducing Costs Three Months Ended Three Months Ended March 31, 2026 March 31, 2025 % (unaudited) (unaudited) CHANGE Operating expenses $21.9 $25.1 (13%) Net loss ($19.7) ($19.7) (0%) Net loss per share ($0.28) ($0.51) (45%) • $37.7M in cash, cash equivalents and short
Slide 17: Q&A
Q&A
Slide 18: The need for therapeutic alternatives to surgery in our RRP community remains immense
“ The need for therapeutic alternatives to surgery in our RRP community remains immense. Every surgery matters, every patient matters, and every patient deserves a treatment that works for them.” Kim McClellan President, RRP Foundation 18
Slide 19: Thank you
Thank you Investors: Peter Vozzo Peter.Vozzo@icrhealthcare.com Media: Jennie Willson Jennie.Willson@inovio.com
INOVIO Pharmaceuticals — Q1 2026 Earnings Presentation on 6ix